A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH).

Trial Profile

A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2013

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hyperlipoproteinaemia type II
  • Focus Pharmacodynamics; Registrational
  • Acronyms ACHIEVE
  • Most Recent Events

    • 23 Jun 2012 Planned number of patients changed from 900 to 1800 as reported by European Clinical Trials Database.
    • 10 Sep 2009 Actual patient number (937) added as reported by ClinicalTrials.gov.
    • 22 May 2008 Status changed from suspended to discontinued, reported by Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top